Target intelligence / Profile preview

Wnt-1 protein (WNT1)

Target
WNT1
Molecular classification
Secreted glycoprotein, Wnt family ligand, Morphogen, Signal transduction molecule
01

Overview

Wnt-1 protein is a highly conserved, secreted glycoprotein belonging to the Wnt family of morphogens. It acts as a canonical Wnt ligand that binds the Frizzled and LRP5/6 receptors on the cell membrane, activating the Wnt/β-catenin signaling pathway. This pathway regulates cell fate, proliferation, differentiation, and migration during embryogenesis and in adult tissue homeostasis. WNT1 is involved in the formation and proliferation of neural progenitor cells, especially in the midbrain and hindbrain. Mutations lead to bone fragility syndromes, while overexpression is linked to tumorigenesis and poor prognosis in various cancers. Its complex folding, lipidation, and hydrophobic nature pose drug development challenges, but make it a crucial target and biomarker for several diseases.

Other names
wingless (Drosophila)INT1 (mouse)WNT1 proto-oncogene
02

Mechanism of action

Inhibition of WNT1-Frizzled binding and/or LRP5/6 recruitment blocks canonical Wnt/β-catenin signaling, which subsequently reduces β-catenin-mediated transcription of oncogenic and developmental target genes (e.g., c-Myc, cyclin D1). Inhibition of secretion and lipidation interferes with WNT1 function.

03

Biological functions

Signal transductionCell proliferationCell fate specificationEmbryonic development (e.g., brain patterning, neural crest expansion)Stem cell maintenance and tissue repairCell survival, differentiation, migration
04

Disease associations

Cancer (including oncogenesis, non-small cell lung cancer)Bone disorders (osteogenesis imperfecta, early-onset osteoporosis)Tumor immune evasion and metastasisOther developmental diseases
05

Safety considerations

WNT1 is essential for normal development; inhibitory strategies risk severe off-target toxicity, especially in bone, nervous system, and tissue homeostasisChallenges in druggability due to protein hydrophobicity, secretion/lipidation dependenceOn-target bone fragility or neurodevelopmental effects in pediatric or adult patients
06

Interacting drugs

Selective Wnt pathway inhibitors have been developed for research use, though no specific WNT1-targeted drugs are approved clinically as of 2025. Example small molecules, antibodies, and pathway inhibitors might include porcupine inhibitors (targeting Wnt secretion) and Frizzled antagonists, but these are pathway-wide, not WNT1-specific.
07

Biomarkers

Elevated WNT1 expression in tumors (e.g., NSCLC) predicts poor prognosis and increased proliferationWNT1 mutation status for bone density disorders

Beyond the preview

Go deeper on Wnt-1 protein (WNT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wnt-1 protein (WNT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call